Hyperfine, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Hyperfine, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $70 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $96 tied up three years earlier. More money tied up than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 99% in 3 years; of every extra $100 of sales, $557 became extra profit. Higher than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-45.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 71% of Healthcare companies in United States.
Cash Locked Ratio
$70For every $100 of sales, $70 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $96 tied up three years earlier.
More money tied up than 97% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$557Sales grew 99% in 3 years; of every extra $100 of sales, $557 became extra profit.
Higher than 94% of Healthcare companies in United States.
Asset Productivity Ratio
+99% / -59%In 3 years sales changed by +99% while total assets changed by -59%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-112.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 85% of Healthcare companies in United States.
Cash Cushion Ratio
+45%Cash, after subtracting all debt, equals 45% of its market value (net cash).
Higher than 76% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Hyperfine, Inc. made a loss over the last year. Hyperfine, Inc. owes $0.42 for every $1 it owns. Hyperfine, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossHyperfine, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.09The share price is 2.09 times Hyperfine, Inc.'s book value per share, lower than 57% of Healthcare companies in United States.
Market cap
$77 MThe total market value of all of Hyperfine, Inc.'s shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$37 MWhat Hyperfine, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.35Net worth divided by the number of shares. The share price of $0.73 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-97.0%Hyperfine, Inc. lost 97.0% of its shareholders' money over the last year, lower than 70% of Healthcare companies in United States.
Owes vs Owns
0.42×Hyperfine, Inc. owes $0.42 for every $1 it owns (low), higher than 50% of Healthcare companies in United States.
Dividend yield
NoneHyperfine, Inc. does not currently pay a dividend.
Revenue growth
+5%Revenue rose 5% in the year to Dec 2025, and grew 26% a year on average over 3 years.
Profit growth
LossHyperfine, Inc. made a loss in each of the last two years.
Profit margin
-262.3%Hyperfine, Inc. lost $262 for every $100 of revenue.
Cash vs debt
Net cashHyperfine, Inc. held $35 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Hyperfine, Inc.: $77 M ÷ $37 M (30 Jun 2026) = 2.1.
What is Hyperfine, Inc.'s return on equity?
Hyperfine, Inc. lost 97.0% of its shareholders' money over the last year, lower than 70% of Healthcare companies in United States.
How much does Hyperfine, Inc. owe compared with what it owns?
Hyperfine, Inc. owes $0.42 for every $1 it owns (low), higher than 50% of Healthcare companies in United States.
Does Hyperfine, Inc. pay a dividend?
No. Hyperfine, Inc. does not currently pay a dividend.
Is Hyperfine, Inc.'s revenue growing?
Revenue rose 5% in the year to Dec 2025, and grew 26% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.